Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of ATYR1940 in adults with facioscapulohumeral muscular dystrophy
NL-OMON44009Active, not recruiting
- Sponsor
- aTyr Pharma
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Resolaris in facioscapulohumeral muscular dystrophy (FSHD), sponsored by aTyr Pharma. Primary endpoints: Physical and neurological examination change from baseline, Adverse events and 5 more. Started Aug 2015; status: active, not recruiting.
02
Drugs
Resolaris
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NL-OMON44009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44009.